Company intelligence / Profile preview

Mist Acquisition

Montréal, Québec, Canada

Ownership: Private
Employees: ~33
Development stage: Other

Overview

FDA approved CARDAMYST (etripamil) nasal spray in December 2025 for acute symptomatic PSVT conversion in adults, supported by Phase 3 RAPID trial showing 64% conversion at 30 minutes vs 31% placebo (median time 17 vs 54 minutes). Ongoing Phase 3 for AFib-RVR.[2][3][4][5]

Therapeutic areas: Cardiovascular
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Mist Acquisition.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mist Acquisition.

Explore the full profile